Wuhan Hvsen Biotechnology Co.,Ltd. (SHE:300871)

China flag China · Delayed Price · Currency is CNY
25.02
-0.94 (-3.62%)
May 12, 2026, 3:04 PM CST
Market Cap5.05B +6.4%
Revenue (ttm)1.74B +25.0%
Net Income286.33M +602.7%
EPS1.42 +487.7%
Shares Out201.78M
PE Ratio17.66
Forward PE22.14
Dividend0.40 (1.54%)
Ex-Dividend DateAug 26, 2025
Volume7,434,400
Average Volume10,990,497
Open26.32
Previous Close25.96
Day's Range24.90 - 26.32
52-Week Range19.08 - 32.62
Beta0.77
RSI42.64
Earnings DateApr 17, 2026

About Wuhan Hvsen Biotechnology

Wuhan Hvsen Biotechnology Co.,Ltd. engages in the research and development, and manufacture of macrolides APIs and preparations in China and internationally. The company offers tylvalosin tartrate powders and raw materials; florfenicol, cefquinome sulfate, and tildipirosin injections; and florfenicol powder/WSP, tylosin tartrate soluble powder, and tywasin premix products. It produces various veterinary drug products of raw materials and preparations, as well as traditional Chinese medicines extractives. Hvsen Biotechnology Co., Ltd. was founde... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2002
Employees 1,133
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 300871
Full Company Profile

Financial Performance

Financial Statements